Floatz logo

Lansoprazole

Idiopathic Pulmonary Fibrosis

Norfolk and Norwich University Hospitals NHS Foundation TrustSmall moleculePhase 3Active
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
73/ 100

Competitive context

110 Active assets in the Idiopathic Pulmonary Fibrosis cohort.

Asset / SponsorPhaseRating
Pirfenidone
Endeavor Biomedicines, Inc.
Phase 4A
N-Acetyl-L-Cysteine
Endeavor Biomedicines, Inc.
Phase 4BBB
Nintedanib
Mannkind Corporation
Phase 4BBB
Nerandomilast
Boehringer Ingelheim
Phase 3BB
hsk44459
Haisco Pharmaceutical Group Co., Ltd.
Phase 3BB

View all 50 →

Same molecule, other indications

Lansoprazole is also rated in:

obesity disorderDormant
BB
Indicative ·
69 / 100
View asset →
gastroesophageal reflux diseaseDormant
BB
Indicative ·
68 / 100
View asset →
metabolic dysfunction-associated steatotic liver diseaseDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →